Go to DAY 2 DAY 3 BACK to EHDN2022
| WELCOME AND INTRODUCTION Chaired by Anne Rosser, Patrick Weydt, Astri Arnesen | ||
| Anne Rosser | Astri Arnesen | Patrick Weydt |
| KEYNOTE SESSION: 150 Years of Huntington’s Disease; Chaired by Anne Rosser and Charles Sabine |
|||
Introduction Charles Sabine |
Living with HD Charlotte Raven and Ed Wild |
||
Mutant Huntingtin: Molecules, Models, Medicines Gillian Bates |
NO VIDEO
Wild-type Huntingtin: Evolution, Structure, Function |
||
| Remembering Lesley Jones |
Anne Rosser and Sarah Tabrizi |
| PLENARY SESSION I: New Genetics of HD; Chaired by Hoa Huu Phuc Nguyen and Flaviano Giorgini |
||
Introduction Hoa Huu Phuc Nguyen and Flaviano Giorgini |
Genetic Modifiers in HD and Somatic Mosacism Darren Monckton |
Non-pathogenic CAG Tract and Gray Matter Microstructure in the Human Brain Larissa Arning |
FAN1 as a Genetic Modifier for HD Progression Joe Hamilton |
HD genomic modifiers: emerging biological, clinical and therapeutic insights Galen Wright |
|
| PARALLEL SESSION I: HTT Structure and Function; Chaired by Chiara Zuccato and Frédéric Saudou |
|||
HTT/HAP40 Complex in the Pathophysiology of HD Stefan Kochanek |
HTT Role in Neuronal Transport Frédéric Saudou |
HTT Exon 1 Aggregation and PTMs Code Hilal Lashuel |
|
| PARALLEL SESSION I: Digital Endpoints; Chaired by Ralf Reilmann and Ahmad Aziz |
|||
| No Video Digital Endpoints – A Perspective from Multiple Sclerosis Bridging to HD Marcus D’Souza |
Lessons Learnt from the Roche HD Digital Monitoring Programme Jonas Dorn |
Lessons Learnt from Q-Motor and Q-Cog in HD Trials Robin Schubert |
|
| PLENARY SESSION II: Approaches to Quality of Life and Clinical Management of HD; Chaired by Alzbeta Mühlbäck and Giorgos Papantoniou |
||
Session Introduction Alzbeta Mühlbäck |
Coping with Symptoms of HD – A Patient Story Tess Persson |
Quality of Life and PROMs for HD G. Bernhard Landwehrmeyer |
Understanding Emotions and Psychiatric Aspects of HD Åsa Petersén |
Management of the Psychiatric Symptoms in HD Duncan McLauchlan |
Panel Discussion All |
| WORKING GROUP SESSION; Chaired by Michael Orth and Kristina Becanovic |
||
Introduction Kristina Becanovic |
Imaging Working Group Rachael Scahill and Nicola Hobbs |
Cognitive Phenotype Working Group Saül Martinez Horta |
Physiotherapy Working Group Anne Kloos, Una Jones, Deb Kegelmeyer |
Systems Modelling Working Group Christian Neri |
Incidental Findings Task Force Nayana Lahiri |
| SHORT COMMUNICATIONS I Chaired by Maria Björkqvist and Marco Onorati |
||
CircHTT, a Novel Circular RNA molecule from the Huntington’s Disease Gene Locus: Functional Characterization and Pathophysiological Implications Jasmin Morandell |
Investigating the Multi-Omic Impact of Huntingtin Aggregates on the D. Elanogaster Brain Megan Bonsor |
Neuropathological Function of the TANK1-Binding Kinase 1 (TBK1) in Mouse Models of Huntington’s Disease Rosanna Parlato |
Juvenile HD Fused Brain Organoids of Dorsal and Ventral Origin to Understand Early Neurodevelopmental Aspects of Neurodegenerative Diseases Karolina Świtońska-Kurkowska |
FAN1 Prevents CRISPR-Cas9 Nickase-Induced Contractions of CAG/CTG Repeats Laura Heraty |
|
| EVENING SESSION: Special Lecture by Nora Guthrie; Chaired by Michaela Winkelmann and Patrick Weydt |
|
Introduction Michaela Winkelmann and Patrick Weydt |
No Video Finding Our Way Nora Guthrie |